Medical Care
Global Gastrointestinal Stromal Tumors Therapeutics Market Research Report 2025
- Mar 13, 25
- ID: 131587
- Pages: 74
- Figures: 75
- Views: 49
The global market for Gastrointestinal Stromal Tumors Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumors Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumors Therapeutics.
The Gastrointestinal Stromal Tumors Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastrointestinal Stromal Tumors Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Stromal Tumors Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascentage Pharma Group International
Bayer AG
Blueprint Medicines Corp
Bristol Myers Squibb Co.
Deciphera Pharmaceuticals Inc
Immunicum AB
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Xencor Inc.
Segment by Type
Oral
Non-oral
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumors Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumors Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumors Therapeutics.
The Gastrointestinal Stromal Tumors Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastrointestinal Stromal Tumors Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Stromal Tumors Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ascentage Pharma Group International
Bayer AG
Blueprint Medicines Corp
Bristol Myers Squibb Co.
Deciphera Pharmaceuticals Inc
Immunicum AB
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Xencor Inc.
Segment by Type
Oral
Non-oral
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumors Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral
1.2.3 Non-oral
1.3 Market by Application
1.3.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Perspective (2020-2031)
2.2 Global Gastrointestinal Stromal Tumors Therapeutics Growth Trends by Region
2.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Gastrointestinal Stromal Tumors Therapeutics Market Dynamics
2.3.1 Gastrointestinal Stromal Tumors Therapeutics Industry Trends
2.3.2 Gastrointestinal Stromal Tumors Therapeutics Market Drivers
2.3.3 Gastrointestinal Stromal Tumors Therapeutics Market Challenges
2.3.4 Gastrointestinal Stromal Tumors Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Revenue
3.1.1 Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gastrointestinal Stromal Tumors Therapeutics Revenue
3.4 Global Gastrointestinal Stromal Tumors Therapeutics Market Concentration Ratio
3.4.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Stromal Tumors Therapeutics Revenue in 2024
3.5 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics Head office and Area Served
3.6 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Product and Application
3.7 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastrointestinal Stromal Tumors Therapeutics Breakdown Data by Type
4.1 Global Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Type (2026-2031)
5 Gastrointestinal Stromal Tumors Therapeutics Breakdown Data by Application
5.1 Global Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
6.2 North America Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
6.4 North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
7.2 Europe Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
7.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
9.2 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ascentage Pharma Group International
11.1.1 Ascentage Pharma Group International Company Details
11.1.2 Ascentage Pharma Group International Business Overview
11.1.3 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Introduction
11.1.4 Ascentage Pharma Group International Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.1.5 Ascentage Pharma Group International Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Introduction
11.2.4 Bayer AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.2.5 Bayer AG Recent Development
11.3 Blueprint Medicines Corp
11.3.1 Blueprint Medicines Corp Company Details
11.3.2 Blueprint Medicines Corp Business Overview
11.3.3 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Introduction
11.3.4 Blueprint Medicines Corp Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.3.5 Blueprint Medicines Corp Recent Development
11.4 Bristol Myers Squibb Co.
11.4.1 Bristol Myers Squibb Co. Company Details
11.4.2 Bristol Myers Squibb Co. Business Overview
11.4.3 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.4.4 Bristol Myers Squibb Co. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.4.5 Bristol Myers Squibb Co. Recent Development
11.5 Deciphera Pharmaceuticals Inc
11.5.1 Deciphera Pharmaceuticals Inc Company Details
11.5.2 Deciphera Pharmaceuticals Inc Business Overview
11.5.3 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Introduction
11.5.4 Deciphera Pharmaceuticals Inc Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.5.5 Deciphera Pharmaceuticals Inc Recent Development
11.6 Immunicum AB
11.6.1 Immunicum AB Company Details
11.6.2 Immunicum AB Business Overview
11.6.3 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Introduction
11.6.4 Immunicum AB Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.6.5 Immunicum AB Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Introduction
11.7.4 Novartis AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.8.4 Pfizer Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.8.5 Pfizer Inc. Recent Development
11.9 Sun Pharmaceutical Industries Ltd
11.9.1 Sun Pharmaceutical Industries Ltd Company Details
11.9.2 Sun Pharmaceutical Industries Ltd Business Overview
11.9.3 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Introduction
11.9.4 Sun Pharmaceutical Industries Ltd Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.9.5 Sun Pharmaceutical Industries Ltd Recent Development
11.10 Xencor Inc.
11.10.1 Xencor Inc. Company Details
11.10.2 Xencor Inc. Business Overview
11.10.3 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.10.4 Xencor Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.10.5 Xencor Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral
1.2.3 Non-oral
1.3 Market by Application
1.3.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Perspective (2020-2031)
2.2 Global Gastrointestinal Stromal Tumors Therapeutics Growth Trends by Region
2.2.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Gastrointestinal Stromal Tumors Therapeutics Market Dynamics
2.3.1 Gastrointestinal Stromal Tumors Therapeutics Industry Trends
2.3.2 Gastrointestinal Stromal Tumors Therapeutics Market Drivers
2.3.3 Gastrointestinal Stromal Tumors Therapeutics Market Challenges
2.3.4 Gastrointestinal Stromal Tumors Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Revenue
3.1.1 Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gastrointestinal Stromal Tumors Therapeutics Revenue
3.4 Global Gastrointestinal Stromal Tumors Therapeutics Market Concentration Ratio
3.4.1 Global Gastrointestinal Stromal Tumors Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Stromal Tumors Therapeutics Revenue in 2024
3.5 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics Head office and Area Served
3.6 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Product and Application
3.7 Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gastrointestinal Stromal Tumors Therapeutics Breakdown Data by Type
4.1 Global Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Type (2026-2031)
5 Gastrointestinal Stromal Tumors Therapeutics Breakdown Data by Application
5.1 Global Gastrointestinal Stromal Tumors Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
6.2 North America Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
6.4 North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
7.2 Europe Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
7.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
9.2 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ascentage Pharma Group International
11.1.1 Ascentage Pharma Group International Company Details
11.1.2 Ascentage Pharma Group International Business Overview
11.1.3 Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Introduction
11.1.4 Ascentage Pharma Group International Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.1.5 Ascentage Pharma Group International Recent Development
11.2 Bayer AG
11.2.1 Bayer AG Company Details
11.2.2 Bayer AG Business Overview
11.2.3 Bayer AG Gastrointestinal Stromal Tumors Therapeutics Introduction
11.2.4 Bayer AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.2.5 Bayer AG Recent Development
11.3 Blueprint Medicines Corp
11.3.1 Blueprint Medicines Corp Company Details
11.3.2 Blueprint Medicines Corp Business Overview
11.3.3 Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Introduction
11.3.4 Blueprint Medicines Corp Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.3.5 Blueprint Medicines Corp Recent Development
11.4 Bristol Myers Squibb Co.
11.4.1 Bristol Myers Squibb Co. Company Details
11.4.2 Bristol Myers Squibb Co. Business Overview
11.4.3 Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.4.4 Bristol Myers Squibb Co. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.4.5 Bristol Myers Squibb Co. Recent Development
11.5 Deciphera Pharmaceuticals Inc
11.5.1 Deciphera Pharmaceuticals Inc Company Details
11.5.2 Deciphera Pharmaceuticals Inc Business Overview
11.5.3 Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Introduction
11.5.4 Deciphera Pharmaceuticals Inc Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.5.5 Deciphera Pharmaceuticals Inc Recent Development
11.6 Immunicum AB
11.6.1 Immunicum AB Company Details
11.6.2 Immunicum AB Business Overview
11.6.3 Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Introduction
11.6.4 Immunicum AB Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.6.5 Immunicum AB Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Details
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Gastrointestinal Stromal Tumors Therapeutics Introduction
11.7.4 Novartis AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.7.5 Novartis AG Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Details
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.8.4 Pfizer Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.8.5 Pfizer Inc. Recent Development
11.9 Sun Pharmaceutical Industries Ltd
11.9.1 Sun Pharmaceutical Industries Ltd Company Details
11.9.2 Sun Pharmaceutical Industries Ltd Business Overview
11.9.3 Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Introduction
11.9.4 Sun Pharmaceutical Industries Ltd Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.9.5 Sun Pharmaceutical Industries Ltd Recent Development
11.10 Xencor Inc.
11.10.1 Xencor Inc. Company Details
11.10.2 Xencor Inc. Business Overview
11.10.3 Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Introduction
11.10.4 Xencor Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
11.10.5 Xencor Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral
Table 3. Key Players of Non-oral
Table 4. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2020-2025)
Table 8. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2026-2031)
Table 10. Gastrointestinal Stromal Tumors Therapeutics Market Trends
Table 11. Gastrointestinal Stromal Tumors Therapeutics Market Drivers
Table 12. Gastrointestinal Stromal Tumors Therapeutics Market Challenges
Table 13. Gastrointestinal Stromal Tumors Therapeutics Market Restraints
Table 14. Global Gastrointestinal Stromal Tumors Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Players (2020-2025)
Table 16. Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumors Therapeutics as of 2024)
Table 17. Ranking of Global Top Gastrointestinal Stromal Tumors Therapeutics Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Gastrointestinal Stromal Tumors Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Headquarters and Area Served
Table 20. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Product and Application
Table 21. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Type (2020-2025)
Table 25. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Type (2026-2031)
Table 27. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Application (2020-2025)
Table 29. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Application (2026-2031)
Table 31. North America Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Ascentage Pharma Group International Company Details
Table 47. Ascentage Pharma Group International Business Overview
Table 48. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product
Table 49. Ascentage Pharma Group International Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 50. Ascentage Pharma Group International Recent Development
Table 51. Bayer AG Company Details
Table 52. Bayer AG Business Overview
Table 53. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product
Table 54. Bayer AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Bayer AG Recent Development
Table 56. Blueprint Medicines Corp Company Details
Table 57. Blueprint Medicines Corp Business Overview
Table 58. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product
Table 59. Blueprint Medicines Corp Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Blueprint Medicines Corp Recent Development
Table 61. Bristol Myers Squibb Co. Company Details
Table 62. Bristol Myers Squibb Co. Business Overview
Table 63. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product
Table 64. Bristol Myers Squibb Co. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Bristol Myers Squibb Co. Recent Development
Table 66. Deciphera Pharmaceuticals Inc Company Details
Table 67. Deciphera Pharmaceuticals Inc Business Overview
Table 68. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product
Table 69. Deciphera Pharmaceuticals Inc Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Deciphera Pharmaceuticals Inc Recent Development
Table 71. Immunicum AB Company Details
Table 72. Immunicum AB Business Overview
Table 73. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product
Table 74. Immunicum AB Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Immunicum AB Recent Development
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product
Table 79. Novartis AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Novartis AG Recent Development
Table 81. Pfizer Inc. Company Details
Table 82. Pfizer Inc. Business Overview
Table 83. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product
Table 84. Pfizer Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Pfizer Inc. Recent Development
Table 86. Sun Pharmaceutical Industries Ltd Company Details
Table 87. Sun Pharmaceutical Industries Ltd Business Overview
Table 88. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product
Table 89. Sun Pharmaceutical Industries Ltd Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Sun Pharmaceutical Industries Ltd Recent Development
Table 91. Xencor Inc. Company Details
Table 92. Xencor Inc. Business Overview
Table 93. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product
Table 94. Xencor Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Xencor Inc. Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Gastrointestinal Stromal Tumors Therapeutics Picture
Figure 2. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Oral Features
Figure 5. Non-oral Features
Figure 6. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Gastrointestinal Stromal Tumors Therapeutics Report Years Considered
Figure 12. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Gastrointestinal Stromal Tumors Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region: 2024 VS 2031
Figure 15. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Players in 2024
Figure 16. Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumors Therapeutics as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Gastrointestinal Stromal Tumors Therapeutics Revenue in 2024
Figure 18. North America Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 20. United States Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 24. Germany Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2020-2031)
Figure 32. China Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 40. Mexico Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 44. Turkey Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Ascentage Pharma Group International Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 48. Bayer AG Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 49. Blueprint Medicines Corp Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 50. Bristol Myers Squibb Co. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 51. Deciphera Pharmaceuticals Inc Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 52. Immunicum AB Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 53. Novartis AG Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 54. Pfizer Inc. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 55. Sun Pharmaceutical Industries Ltd Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 56. Xencor Inc. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Table 1. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Oral
Table 3. Key Players of Non-oral
Table 4. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2020-2025)
Table 8. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2026-2031)
Table 10. Gastrointestinal Stromal Tumors Therapeutics Market Trends
Table 11. Gastrointestinal Stromal Tumors Therapeutics Market Drivers
Table 12. Gastrointestinal Stromal Tumors Therapeutics Market Challenges
Table 13. Gastrointestinal Stromal Tumors Therapeutics Market Restraints
Table 14. Global Gastrointestinal Stromal Tumors Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Players (2020-2025)
Table 16. Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumors Therapeutics as of 2024)
Table 17. Ranking of Global Top Gastrointestinal Stromal Tumors Therapeutics Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Gastrointestinal Stromal Tumors Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Headquarters and Area Served
Table 20. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Product and Application
Table 21. Global Key Players of Gastrointestinal Stromal Tumors Therapeutics, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Type (2020-2025)
Table 25. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Type (2026-2031)
Table 27. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Application (2020-2025)
Table 29. Global Gastrointestinal Stromal Tumors Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Gastrointestinal Stromal Tumors Therapeutics Revenue Market Share by Application (2026-2031)
Table 31. North America Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Ascentage Pharma Group International Company Details
Table 47. Ascentage Pharma Group International Business Overview
Table 48. Ascentage Pharma Group International Gastrointestinal Stromal Tumors Therapeutics Product
Table 49. Ascentage Pharma Group International Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 50. Ascentage Pharma Group International Recent Development
Table 51. Bayer AG Company Details
Table 52. Bayer AG Business Overview
Table 53. Bayer AG Gastrointestinal Stromal Tumors Therapeutics Product
Table 54. Bayer AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 55. Bayer AG Recent Development
Table 56. Blueprint Medicines Corp Company Details
Table 57. Blueprint Medicines Corp Business Overview
Table 58. Blueprint Medicines Corp Gastrointestinal Stromal Tumors Therapeutics Product
Table 59. Blueprint Medicines Corp Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Blueprint Medicines Corp Recent Development
Table 61. Bristol Myers Squibb Co. Company Details
Table 62. Bristol Myers Squibb Co. Business Overview
Table 63. Bristol Myers Squibb Co. Gastrointestinal Stromal Tumors Therapeutics Product
Table 64. Bristol Myers Squibb Co. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 65. Bristol Myers Squibb Co. Recent Development
Table 66. Deciphera Pharmaceuticals Inc Company Details
Table 67. Deciphera Pharmaceuticals Inc Business Overview
Table 68. Deciphera Pharmaceuticals Inc Gastrointestinal Stromal Tumors Therapeutics Product
Table 69. Deciphera Pharmaceuticals Inc Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Deciphera Pharmaceuticals Inc Recent Development
Table 71. Immunicum AB Company Details
Table 72. Immunicum AB Business Overview
Table 73. Immunicum AB Gastrointestinal Stromal Tumors Therapeutics Product
Table 74. Immunicum AB Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 75. Immunicum AB Recent Development
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Gastrointestinal Stromal Tumors Therapeutics Product
Table 79. Novartis AG Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Novartis AG Recent Development
Table 81. Pfizer Inc. Company Details
Table 82. Pfizer Inc. Business Overview
Table 83. Pfizer Inc. Gastrointestinal Stromal Tumors Therapeutics Product
Table 84. Pfizer Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 85. Pfizer Inc. Recent Development
Table 86. Sun Pharmaceutical Industries Ltd Company Details
Table 87. Sun Pharmaceutical Industries Ltd Business Overview
Table 88. Sun Pharmaceutical Industries Ltd Gastrointestinal Stromal Tumors Therapeutics Product
Table 89. Sun Pharmaceutical Industries Ltd Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Sun Pharmaceutical Industries Ltd Recent Development
Table 91. Xencor Inc. Company Details
Table 92. Xencor Inc. Business Overview
Table 93. Xencor Inc. Gastrointestinal Stromal Tumors Therapeutics Product
Table 94. Xencor Inc. Revenue in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Xencor Inc. Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Gastrointestinal Stromal Tumors Therapeutics Picture
Figure 2. Global Gastrointestinal Stromal Tumors Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Oral Features
Figure 5. Non-oral Features
Figure 6. Global Gastrointestinal Stromal Tumors Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Application: 2024 VS 2031
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Gastrointestinal Stromal Tumors Therapeutics Report Years Considered
Figure 12. Global Gastrointestinal Stromal Tumors Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Gastrointestinal Stromal Tumors Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Region: 2024 VS 2031
Figure 15. Global Gastrointestinal Stromal Tumors Therapeutics Market Share by Players in 2024
Figure 16. Global Top Gastrointestinal Stromal Tumors Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastrointestinal Stromal Tumors Therapeutics as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Gastrointestinal Stromal Tumors Therapeutics Revenue in 2024
Figure 18. North America Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 20. United States Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 24. Germany Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Share by Region (2020-2031)
Figure 32. China Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 40. Mexico Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Gastrointestinal Stromal Tumors Therapeutics Market Share by Country (2020-2031)
Figure 44. Turkey Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Gastrointestinal Stromal Tumors Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Ascentage Pharma Group International Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 48. Bayer AG Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 49. Blueprint Medicines Corp Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 50. Bristol Myers Squibb Co. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 51. Deciphera Pharmaceuticals Inc Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 52. Immunicum AB Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 53. Novartis AG Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 54. Pfizer Inc. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 55. Sun Pharmaceutical Industries Ltd Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 56. Xencor Inc. Revenue Growth Rate in Gastrointestinal Stromal Tumors Therapeutics Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232